2022
Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia
Kwon J, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Chambers HF, Fowler VG, Huskins WC, Pettigrew M. Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. The Journal Of Infectious Diseases 2022, 226: 1109-1119. PMID: 35249113, PMCID: PMC9492313, DOI: 10.1093/infdis/jiac082.Peer-Reviewed Original ResearchConceptsAAD groupAntibiotic-associated diarrheaCommunity-acquired pneumoniaCommon side effectsStudy days 1Days of diarrheaPatient characteristicsAntibiotic therapyNineteen childrenStool samplesSide effectsDay 1Microbiome disruptionMicrobiota profilesGastrointestinal microbiotaMicrobiota characteristicsDiarrheaBacteroides speciesPneumoniaChildrenAntibioticsΒ-lactamsAADBaseline abundanceDysbiosis
2002
Antimicrobial Activities of BMS-284756 Compared with Those of Fluoroquinolones and β-Lactams against Gram-Positive Clinical Isolates
Bassetti M, Dembry L, Farrel P, Callan D, Andriole V. Antimicrobial Activities of BMS-284756 Compared with Those of Fluoroquinolones and β-Lactams against Gram-Positive Clinical Isolates. Antimicrobial Agents And Chemotherapy 2002, 46: 234-238. PMID: 11751142, PMCID: PMC126992, DOI: 10.1128/aac.46.1.234-238.2002.Peer-Reviewed Original ResearchConceptsBMS-284756Clinical isolatesGram-positive clinical isolatesResistant coagulase-negative staphylococciBeta-hemolytic streptococciAmoxicillin-clavulanic acidPositive clinical isolatesResistant Staphylococcus aureusCoagulase-negative staphylococciPiperacillin-tazobactamStreptococcus viridansStreptococcus pneumoniaeStaphylococcus aureusΒ-lactamsActive agentsIsolatesCeftriaxoneAntibacterial activityImipenemMoxifloxacinPneumoniaeViridansFluoroquinolones
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply